Which feature best distinguishes cyclophosphamide from other alkylating agents in terms of its unique clinical toxicity and mechanism?

Explanation

## Distinguishing Feature of Cyclophosphamide **Key Point:** Cyclophosphamide is uniquely associated with hemorrhagic cystitis, a bladder toxicity caused by its metabolite acrolein, not the parent drug itself. ### Mechanism of Acrolein-Induced Cystitis Cyclophosphamide undergoes hepatic metabolism to produce active alkylating metabolites (phosphoramide mustard) AND the toxic metabolite acrolein. Acrolein is excreted unchanged in urine and directly damages the urothelium, causing: 1. Acute hemorrhagic cystitis (during treatment) 2. Chronic cystitis with fibrosis (long-term sequela) 3. Increased risk of bladder cancer (years later) ### Prevention Strategies | Strategy | Mechanism | Efficacy | |----------|-----------|----------| | Aggressive hydration | Dilutes urine acrolein concentration | High | | Frequent voiding | Reduces bladder dwell time | High | | Mesna (2-mercaptoethanesulfonate) | Inactivates acrolein in bladder | Very high (standard) | | Catheterization (rare) | Continuous drainage | Rarely needed | **High-Yield:** Mesna is a **uroprotective agent** — it binds acrolein in the bladder lumen, preventing epithelial damage. Always given with high-dose cyclophosphamide. ### Clinical Pearl Hemorrhagic cystitis is **pathognomonic** for cyclophosphamide among alkylating agents. Other agents (nitrogen mustard, busulfan, melphalan) do NOT produce this toxicity because they lack the acrolein metabolite. **Mnemonic:** **CYSTO** — **CY**clophosphamide → **CYSTO**itis (hemorrhagic cystitis) [cite:KD Tripathi 8e Ch 62]